Interferon and amantadine in naive chronic hepatitis C: A double-blind, randomized, placebo-controlled trial

Hepatology

Volumn 35, Issue 2, 2002, Pages 447-454

  Helbling, Beat ^a   Stamenic, Ivan ^a   Viani, Francesco ^b   Gonvers, Jean Jacques ^b   Dufour, Jean Francois ^c   Reichen, Jurg ^c   Cathomas, Gieri ^a,d   Steuerwald, Michael ^d   Borovicka, Jan ^e   Sagmeister, Markus ^a   Renner, Eberhard L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Kantonsspital Liestal   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AMANTADINE; PLACEBO; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; VIREMIA; VIRUS TITRATION;

EID: 18244398956     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.31168     Document Type: Article

References (43)

1. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome
2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
3. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
4. Peginterferon alfa-2a in patients with chronic hepatitis C
5. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
6. Pegylated (40kDa) interferon alfa-2a (Pegasys) in combination with ribavirin: Efficacy and safety results form a phase III, randomized, actively-controlled, multicenter study
7. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavrin for initial treatment of chronic hepatitis C: A randomised trial
8. The roles of vaccination and amantadine prophylaxis in controlling an out-break of influenza A (H3N2) in a nursing home
9. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
10. Prophylaxis and treatment of influenza
11. Antiviral agents for respiratory infections
12. Inhibition of dengue virus replication by amantadine hydrochloride
13. Influenza virus. Amantadine blocks the channel
14. Inhibition of uncoating of fowl plague virus by l-adamantanamine hydrochloride
15. The effect of amantadine on mouse hepatitis virus replication
16. Arenaviruses: Inhibition by amantadine hydrochloride
17. Treatment of chronic hepatitis C with amantadine
18. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients
19. Amantadine monotherapy of chronic hepatitis C patients infected with genotype lb
20. Interferon alpha 2b and ribavirin vs interferon alpha 2b and amantadine for chronic hepatitis C (non responder): A multicenter, randomized double-blind trial
21. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy
22. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C
23. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin
24. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
25. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and with out amantadine as initial treatment for chronic hepatitis C
26. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients
27. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: A UK multicentre study
28. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C
29. Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays
30. Histological grading and staging of chronic hepatitis
31. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C
32. Antiviral therapy for patients with chronic hepatitis C
33. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
34. Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation
35. Distribution of memantine in brain, liver, and blood of the rat
36. In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients
37. Recent advances in the molecular biology of hepatitis C virus
38. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C
39. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
40. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C
41. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction